Cover Kidney News
Volume/Issue:
Volume 13: Issue 3
Page:
18
Publication Date:
01 Mar 2021
Online Publication Date:
05 Mar 2021
  • Figure 1.
    View in gallery
    Figure 1.

    Mechanism for how soluble ACE2 1–618-ABD neutralizes SARS-CoV-2

Figure 1.

Mechanism for how soluble ACE2 1–618-ABD neutralizes SARS-CoV-2
  • 1.

    Khan A, et al.. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 2017; 21:234. doi: 10.1186/s13054-017-1823-x

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Zoufaly A, et al.. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med 2020; 8:1154−1158. doi: 10.1016/S2213-2600(20)30418-5

  • 3.

    Monteil V, et al.. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181:905−913.e7. doi: 10.1016/j.cell.2020.04.004

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Wysocki J, et al.. A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J Am Soc Nephrol [published online ahead of print February 1, 2021]. doi: 10.1681/asn.2020101537; https://jasn.asnjournals.org/content/early/2021/01/29/ASN.2020101537

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Liu P, et al.. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int 2018; 94:114−125. doi: 10.1016/j.kint.2018.01.029

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Chan KK, et al.. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 2020; 369:1261−1265. doi: 10.1126/science.abc0870

Editorial Type:
Features

An Update on Novel Soluble ACE2 Therapeutics to Treat SARS-CoV-2: Insights from a Preclinical Study

Andrew M. South Andrew M. South, MD, MS, is with the Departments of Pediatrics-Section of Nephrology and Surgery-Hypertension and Vascular Research, Division of Public Health Sciences, and Department of Epidemiology and Prevention, Brenner Children’s Hospital, Wake Forest School of Medicine, Winston-Salem, NC. Matthew A. Sparks, MD, FASN, is Assistant Professor of Medicine, Associate Program Director of Nephrology Fellowship, and Director of Medical Student Research in the Department of Medicine, Duke University, and staff physician for the Durham VA Health System, Durham, NC.

Search for other papers by Andrew M. South in
Current site
Google Scholar
PubMed Close
and
Matthew A. Sparks Andrew M. South, MD, MS, is with the Departments of Pediatrics-Section of Nephrology and Surgery-Hypertension and Vascular Research, Division of Public Health Sciences, and Department of Epidemiology and Prevention, Brenner Children’s Hospital, Wake Forest School of Medicine, Winston-Salem, NC. Matthew A. Sparks, MD, FASN, is Assistant Professor of Medicine, Associate Program Director of Nephrology Fellowship, and Director of Medical Student Research in the Department of Medicine, Duke University, and staff physician for the Durham VA Health System, Durham, NC.

Search for other papers by Matthew A. Sparks in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 13: Issue 3
Publication Date:
01 Mar 2021
Page:
18
Restricted access
Save